Forxiga Resources

Find useful resources on managing outcomes in insufficiently controlled type 2 diabetes or symptomatic HFrEF.

Find useful resources on managing outcomes in insufficiently controlled type 2 diabetes or symptomatic HFrEF.

Webinars

AstraZeneca regularly hosts webinars on the latest developments in type 2 diabetes (T2D) and heart failure. Check back soon to find details of our upcoming webinars.

Videos

Heart failure: a call to action

Professor Martin Cowie discusses strategies to improve heart failure care in the UK.

DAPA HF Trial Overview

Hear Professor Mark Petrie, Professor of Cardiology at the University of Glasgow, discuss the the design and results of the DAPA-HF Trial.

Dapagliflozin Patient Identification Resource

The Dapagliflozin Patient Identification Resource is a promotional resource, designed to support the NHS to improve the care of patients living with T2D or HFrEF who may be suitable for Dapagliflozin in relation to its licence.

Using the GP clinical systems, the Dapagliflozin Patient Identification Resource enables the user to take a systematic, consistent and efficient approach to identify patients who may be considered for Dapagliflozin, in line with the current licence.

Please note: not all patients found in the resource will definitely benefit or are suitable for Forxiga. This judgement remains with the clinician at all times. This resource does not find every patient who will benefit from Forxiga, but instead who are possibly suitable within the license and SMPC.

This resource is provided to GP practices (GPs, Nurses, Practice Managers and appropriate administrative staff) as well as Primary Care Networks, to support quality of care at a practice level.

The resource is available for those UK based practices who have access to EMIS and SystmOne.

The resource consists of:

Importable clinical systems searches.
A step-by-step instruction guide.

The easy step-by-step instruction guide, will enable the user to:

Download, import and run the searches.
View the search criteria specification and understand what the criteria comprises of.

This resource only identifies patients potentially suitable for Forxiga (Dapagliflozin), but it does not replace the need for a clinical assessment of patients identified.
It is important to note that all decision making and clinical judgement throughout this process should remain with the Healthcare Professional.

FAQ

No, AstraZeneca do not see or remove any data from the practice.

The Dapagliflozin Patient Identification Resource can be used by GPs, Practice Nurses, Managers and Administrative staff. It is only available for those UK based practices who have access to EMIS and SystmOne.

Please consult your local policies and relevant teams for data sharing.

Once you have downloaded and imported the searches onto your GP Clinical System they can be utilised until your practice or AstraZeneca recommends that you delete them.

AstraZeneca may retain certain personal data of the user, including but not limited to the name of registered user, job title, email address and GP Practice name, address and practice identification Code.

AstraZeneca will store the name of registered user, job title and email address solely for the purposes of registration and for the purposes of contacting the GP Practice for any Maintenance Releases.

AstraZeneca shall not share any personal data with any other third parties without prior written consent.

AstraZeneca will store all User personal data using adequate security measures and will only store such data for the time period required by local laws and AstraZeneca´s internal policies and procedures.

Please consult your local IT governance policies and relevant teams in relation to IT governance.

The resource will be available to you once you have completed the registration form on the Forxiga website.

The instruction guide which supports the Dapagliflozin Patient Identification Resource includes the search specification used to identify specific cohorts of patients. The full specification can be viewed using a link provided in the instruction guide.

The searches have been validated in live GP practices by commissioned HCP’s.

AstraZeneca requests individual NHS organisations to request access by completing a registration process via the Forxiga.co.uk website.

Download

Forxiga Patient Booklet: Type 2 Diabetes – Glycaemic Control

A quick guide that introduces your patients to Forxiga and helps them to better understand type 2 diabetes.

Download

Forxiga Patient Booklet: Heart Failure

A quick guide that introduces your patients to Forxiga and helps them to better understand heart failure.

Download

Formulary Pack

This document provides a summary of key information required when making formulary and guideline decisions regarding Forxiga.

Download

Forxiga in heart failure (HFrEF): Key clinical considerations for prescribers

This document outlines key clinical considerations when prescribing Forxiga in heart failure and type 2 diabetes.

Download

Tools

Heart Failure Care Review Tool

 

The Burden of Disease dashboard has been developed by AstraZeneca to facilitate discussion with local NHS organisations on the management of patients diagnosed with Heart Failure and also to look at the frequently associated risks and complications of comorbidities such as diabetes. The content includes environmental data and service performance measures to highlight opportunities for improvements in patient outcomes and efficiency savings.

Heart Failure Budget Impact Model

 

The purpose of the Budget Impact Model (BIM) is to demonstrate the estimated change in expenditure when Forxiga is included in the pathway to treat heart failure patients in a selected population over time. The BIM will inform discussions between representatives of AstraZeneca and the NHS, and will show the comparative change in spend vs. outcomes for budget planning purposes by local, regional and national-level decision makers, especially where expenditure in one budget is offset by efficiency savings in another.

Forxiga Heart Failure Value Proposition

 

This value proposition has been developed to facilitate discussion between AstraZeneca representatives and NHS Health Care Professionals and payers regarding unmet need in heart failure, nationally and locally, in prevalence/hospitalisations, patient pathways and treatment options across the UK. The Heart Failure value proposition presents data from the DAPA- HF trial. It also presents the potential economic and patient value of prescribing Forxiga in HFrEF.

Enhanced Diabetes Tool

 

The purpose of the Enhanced Diabetes Tool is to inform discussions between representatives of AstraZeneca and the NHS, regarding national, regional and local environment data related to spend vs. outcomes in diabetes services and to estimate via Budget Impact Models the cost consequences of prescribing Forxiga within a selected patient cohort.

Forxiga T2D Value Proposition

 

This value proposition has been developed to facilitate discussion between AstraZeneca representatives and NHS Health Care Professionals and payers regarding increased risk due to complications in T2DM patients. It focuses on the unmet need in heart failure and kidney disease and the national and local burden of complications and related hospitalisations in T2DM patients with heart failure. It also presents the potential economic and patient value of prescribing Forxiga in T2D.

GB-27763 | DOP: June 2021